Balance Sheet

Current Liabilities	1.5B
Accounts Payable	146.8m
Accrued Liabilities	116.3m
Short-Term Debt	1.1B
Other Current Liabilities	124.4m
Non-Current Liabilities	197.3m
Long-Term Debt	106.9m
Other Non-Current Liabilities	90.4m

Currency: CNY

	Dec-2018	Dec-2019	Dec-2020	Dec-2021	Dec-2022	Dec-2023
Assets
Cash & Cash Equivalents	83	94	222	1 478	1 345	848
Cash	0	0	0	0	1 345	848
Cash Equivalents	83	94	222	1 478	0	0
Short-Term Investments	9	0	796	1 976	1 919	2 633
Total Receivables	53	81	234	334	855	366
Accounts Receivables	40	71	226	322	838	352
Other Receivables	13	10	8	12	17	14
Inventory	28	53	132	242	364	346
Other Current Assets	2	4	12	21	82	37
Total Current Assets	176	233	1 396	4 051	4 565	4 230
PP&E Net	28	35	134	343	785	836
PP&E Gross	28	35	134	343	785	836
Accumulated Depreciation	10	16	27	74	387	485
Intangible Assets	1	2	7	17	50	101
Goodwill	0	0	0	0	130	130
Note Receivable	0	0	0	0	0	0
Long-Term Investments	0	0	0	18	22	47
Other Long-Term Assets	46	54	75	178	452	401
Other Assets	0	0	0	0	130	130
Total Assets	251 N/A	324 +29%	1 612 +397%	4 607 +186%	6 005 +30%	5 746 -4%
Liabilities
Accounts Payable	13	17	59	119	293	147
Accrued Liabilities	14	28	55	106	272	116
Short-Term Debt	31	36	1	0	298	1 132
Current Portion of Long-Term Debt	0	0	0	31	58	46
Other Current Liabilities	22	28	124	132	233	78
Total Current Liabilities	80	108	239	387	1 154	1 520
Long-Term Debt	0	0	0	60	128	107
Deferred Income Tax	0	0	0	1	11	2
Minority Interest	0	0	0	0	3	0
Other Liabilities	5	16	40	32	100	89
Total Liabilities	85 N/A	124 +47%	279 +125%	480 +72%	1 396 +191%	1 717 +23%
Equity
Common Stock	15	15	360	400	400	400
Retained Earnings	34	8	627	1 305	1 780	1 209
Additional Paid In Capital	185	193	345	2 422	2 429	2 442
Treasury Stock	0	0	0	0	0	20
Other Equity	0	0	0	0	0	2
Total Equity	166 N/A	200 +20%	1 332 +566%	4 127 +210%	4 609 +12%	4 029 -13%
Total Liabilities & Equity	251 N/A	324 +29%	1 612 +397%	4 607 +186%	6 005 +30%	5 746 -4%
Shares Outstanding
Common Shares Outstanding	400	400	400	400	400	399

Nanjing Vazyme Biotech Co Ltd
SSE:688105